Liao, S.-S.; Deng, Y.-L.; Hsu, C.-Y.; Lee, H.-T.; Li, C.-R.; Yang, C.-C.
Denosumab in the Management of Glucocorticoid-Induced Osteoporosis: Long-Term Efficacy and Secondary Fracture Outcomes. J. Clin. Med. 2025, 14, 1633.
https://doi.org/10.3390/jcm14051633
AMA Style
Liao S-S, Deng Y-L, Hsu C-Y, Lee H-T, Li C-R, Yang C-C.
Denosumab in the Management of Glucocorticoid-Induced Osteoporosis: Long-Term Efficacy and Secondary Fracture Outcomes. Journal of Clinical Medicine. 2025; 14(5):1633.
https://doi.org/10.3390/jcm14051633
Chicago/Turabian Style
Liao, Sian-Siang, Ya-Lian Deng, Chiann-Yi Hsu, Hsu-Tung Lee, Chi-Ruei Li, and Chi-Chan Yang.
2025. "Denosumab in the Management of Glucocorticoid-Induced Osteoporosis: Long-Term Efficacy and Secondary Fracture Outcomes" Journal of Clinical Medicine 14, no. 5: 1633.
https://doi.org/10.3390/jcm14051633
APA Style
Liao, S.-S., Deng, Y.-L., Hsu, C.-Y., Lee, H.-T., Li, C.-R., & Yang, C.-C.
(2025). Denosumab in the Management of Glucocorticoid-Induced Osteoporosis: Long-Term Efficacy and Secondary Fracture Outcomes. Journal of Clinical Medicine, 14(5), 1633.
https://doi.org/10.3390/jcm14051633